APP and Alzheimer disease: Acitretin (Neotigason), which increases APP processing along the non-amyloidogenic pathway in vitro, in primary cells, and in AD model mice (Tippmann et al., 2009; Reinhardt et al., 2016), was given to patients with mild to moderate AD for 4 weeks.